{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:54:31Z","timestamp":1791312871798,"version":"4.3.1"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.cellsig.2024.111405","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T12:19:44Z","timestamp":1726143584000},"page":"111405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["NK cell-based immunotherapy in hepatocellular carcinoma: An attractive therapeutic option for the next decade"],"prefix":"10.1016","volume":"124","author":[{"given":"Xinyi","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianye","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cellsig.2024.111405_bb0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"15","key":"10.1016\/j.cellsig.2024.111405_bb0010","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular Carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111405_bb0015","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"10","key":"10.1016\/j.cellsig.2024.111405_bb0020","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"10126","key":"10.1016\/j.cellsig.2024.111405_bb0025","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet (London, England)."},{"issue":"3\u20134","key":"10.1016\/j.cellsig.2024.111405_bb0030","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000343837","article-title":"Immunotherapeutic approaches to hepatocellular carcinoma treatment","volume":"1","author":"Miamen","year":"2012","journal-title":"Liver Cancer"},{"issue":"2","key":"10.1016\/j.cellsig.2024.111405_bb0035","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3322\/caac.21818","article-title":"Immunosurveillance in clinical cancer management","volume":"74","author":"Kroemer","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"20","key":"10.1016\/j.cellsig.2024.111405_bb0040","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111405_bb0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.cellsig.2024.111405_bb0050","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.cellsig.2024.111405_bb0055","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung Cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.cellsig.2024.111405_bb0060","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/aps.2015.41","article-title":"Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy","volume":"36","author":"Sun","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"issue":"6","key":"10.1016\/j.cellsig.2024.111405_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/cells10061332","article-title":"Natural killer cells and T cells in hepatocellular carcinoma and viral hepatitis: current status and perspectives for future immunotherapeutic approaches","volume":"10","author":"Kalathil","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.cellsig.2024.111405_bb0070","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1084\/jem.20010934","article-title":"Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells","volume":"195","author":"Piccioli","year":"2002","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.cellsig.2024.111405_bb0075","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1182\/blood-2005-03-1154","article-title":"Natural-killer cells and dendritic cells: \u201cl\u2019union fait la force\u201d","volume":"106","author":"Walzer","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.cellsig.2024.111405_bb0080","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fimmu.2016.00251","article-title":"Recognition and regulation of T cells by NK cells","volume":"7","author":"Pallmer","year":"2016","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.cellsig.2024.111405_bb0085","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.4049\/jimmunol.164.8.4055","article-title":"Fractalkine-mediated endothelial cell injury by NK cells","volume":"164","author":"Yoneda","year":"2000","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.cellsig.2024.111405_bb0090","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/hep.23054","article-title":"Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor","volume":"50","author":"Hoechst","year":"2009","journal-title":"Hepatology (Baltimore, Md)."},{"issue":"3","key":"10.1016\/j.cellsig.2024.111405_bb0095","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/hep.26192","article-title":"Monocyte\/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48\/2B4 interactions","volume":"57","author":"Wu","year":"2013","journal-title":"Hepatology (Baltimore, Md)."},{"issue":"11","key":"10.1016\/j.cellsig.2024.111405_bb0100","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41577-018-0061-z","article-title":"Natural killer cells and other innate lymphoid cells in cancer","volume":"18","author":"Chiossone","year":"2018","journal-title":"Nat. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.cellsig.2024.111405_bb0105","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","article-title":"The biology of human natural killer-cell subsets","volume":"22","author":"Cooper","year":"2001","journal-title":"Trends Immunol."},{"issue":"3","key":"10.1016\/j.cellsig.2024.111405_bb0110","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.blre.2005.10.001","article-title":"Human natural killer cell development and biology","volume":"20","author":"Farag","year":"2006","journal-title":"Blood Rev."},{"key":"10.1016\/j.cellsig.2024.111405_bb0115","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3389\/fimmu.2017.00699","article-title":"Human CD56(dim)CD16(dim) cells as an individualized natural killer cell subset","volume":"8","author":"Amand","year":"2017","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.cellsig.2024.111405_bb0120","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1615\/CritRevImmunol.2024052486","article-title":"Current and future states of natural killer cell-based immunotherapy in hepatocellular carcinoma","volume":"44","author":"Nguyen","year":"2024","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.cellsig.2024.111405_bb0125","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.3389\/fimmu.2019.02078","article-title":"Human NK cell development: one road or many?","volume":"10","author":"Cichocki","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellsig.2024.111405_bb0130","doi-asserted-by":"crossref","first-page":"1061959","DOI":"10.3389\/fimmu.2022.1061959","article-title":"Inflammatory-driven NK cell maturation and its impact on pathology","volume":"13","author":"Bourayou","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.cellsig.2024.111405_bb0135","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.4049\/jimmunol.1701675","article-title":"Loss of canonical notch signaling affects multiple steps in NK cell development in mice","volume":"201","author":"Chaves","year":"2018","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.cellsig.2024.111405_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061553","article-title":"Tissue-resident NK cells: development, maturation, and clinical relevance","volume":"12","author":"Hashemi","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.cellsig.2024.111405_bb0145","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.3389\/fimmu.2019.02278","article-title":"NK cell metabolism and tumor microenvironment","volume":"10","author":"Terr\u00e9n","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellsig.2024.111405_bb0150","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.3389\/fimmu.2020.02156","article-title":"Inhibitory receptors and checkpoints in human NK cells, implications for the immunotherapy of Cancer","volume":"11","author":"Sivori","year":"2020","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.cellsig.2024.111405_bb0155","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","article-title":"Natural killer cells in antitumour adoptive cell immunotherapy","volume":"22","author":"Laskowski","year":"2022","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.cellsig.2024.111405_bb0160","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.22034","article-title":"Liver: an organ with predominant innate immunity","volume":"47","author":"Gao","year":"2008","journal-title":"Hepatology (Baltimore, Md)."},{"issue":"4","key":"10.1016\/j.cellsig.2024.111405_bb0165","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/hep.26115","article-title":"Natural killer cells in liver disease","volume":"57","author":"Tian","year":"2013","journal-title":"Hepatology (Baltimore, Md)."},{"issue":"3\u20134","key":"10.1016\/j.cellsig.2024.111405_bb0170","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jaut.2009.07.010","article-title":"Application of tissue-specific NK and NKT cell activity for tumor immunotherapy","volume":"33","author":"Subleski","year":"2009","journal-title":"J. Autoimmun."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111405_bb0175","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/35095564","article-title":"Natural killer cells, viruses and cancer","volume":"1","author":"Cerwenka","year":"2001","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.cellsig.2024.111405_bb0180","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.immuni.2008.02.016","article-title":"NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy","volume":"28","author":"Guerra","year":"2008","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.cellsig.2024.111405_bb0185","first-page":"17","article-title":"Diminished absolute counts of CD56dim and CD56bright natural killer cells in peripheral blood from Egyptian patients with hepatocellular carcinoma","volume":"16","author":"Fathy","year":"2009","journal-title":"Egypt. J. Immunol."},{"issue":"8","key":"10.1016\/j.cellsig.2024.111405_bb0190","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.4049\/jimmunol.1301889","article-title":"CD56(bright)perforin(low) noncytotoxic human NK cells are abundant in both healthy and neoplastic solid tissues and recirculate to secondary lymphoid organs via afferent lymph","volume":"192","author":"Carrega","year":"2014","journal-title":"J. Immunol."},{"issue":"11","key":"10.1016\/j.cellsig.2024.111405_bb0195","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.7314\/APJCP.2012.13.11.5909","article-title":"Associations between infiltrating lymphocyte subsets and hepatocellular carcinoma","volume":"13","author":"Guo","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"10","key":"10.1016\/j.cellsig.2024.111405_bb0200","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma","volume":"15","author":"Llovet","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.cellsig.2024.111405_bb0205","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1158\/2326-6066.CIR-18-0757","article-title":"Accumulation of tumor-infiltrating CD49a(+) NK cells correlates with poor prognosis for human hepatocellular carcinoma","volume":"7","author":"Sun","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"8","key":"10.1016\/j.cellsig.2024.111405_bb0210","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1154249","article-title":"Natural killer cells phenotypic characterization as an outcome predictor of HCV-linked HCC after curative treatments","volume":"5","author":"Cariani","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cellsig.2024.111405_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109637","article-title":"Comprehensive characterization of tumor infiltrating natural killer cells and clinical significance in hepatocellular carcinoma based on gene expression profiles","volume":"121","author":"Wu","year":"2020","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.cellsig.2024.111405_bb0220","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1136\/gutjnl-2011-300509","article-title":"Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma","volume":"61","author":"Chew","year":"2012","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.cellsig.2024.111405_bb0225","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/gutjnl-2018-316408","article-title":"Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial","volume":"68","author":"Pinyol","year":"2019","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111405_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100872","article-title":"Liraglutide activates nature killer cell-mediated antitumor responses by inhibiting IL-6\/STAT3 signaling in hepatocellular carcinoma","volume":"14","author":"Lu","year":"2021","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.cellsig.2024.111405_bb0235","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/JIR.S166564","article-title":"IL-1\u03b1 correlates with severity of hepatitis C virus-related liver diseases","volume":"11","author":"Tawfik","year":"2018","journal-title":"J. Inflamm. Res."},{"issue":"29","key":"10.1016\/j.cellsig.2024.111405_bb0240","doi-asserted-by":"crossref","first-page":"E5900","DOI":"10.1073\/pnas.1706559114","article-title":"Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses","volume":"114","author":"Chew","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.cellsig.2024.111405_bb0245","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.imlet.2018.11.004","article-title":"Human natural killer cells and other innate lymphoid cells in cancer: friends or foes?","volume":"201","author":"Vacca","year":"2018","journal-title":"Immunol. Lett."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111405_bb0250","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/hep.30347","article-title":"Human CD96 correlates to natural killer cell exhaustion and predicts the prognosis of human hepatocellular carcinoma","volume":"70","author":"Sun","year":"2019","journal-title":"Hepatology (Baltimore, Md)."},{"key":"10.1016\/j.cellsig.2024.111405_bb0255","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3389\/fonc.2020.00971","article-title":"ULBP1 is elevated in human hepatocellular carcinoma and predicts outcome","volume":"10","author":"Easom","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cellsig.2024.111405_bb0260","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.3389\/fimmu.2018.01808","article-title":"The paradoxical role of NKG2D in Cancer immunity","volume":"9","author":"Sheppard","year":"2018","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.cellsig.2024.111405_bb0265","first-page":"6550","article-title":"Single-cell data revealed exhaustion of characteristic NK cell subpopulations and T cell subpopulations in hepatocellular carcinoma","volume":"16","author":"Cui","year":"2024","journal-title":"Aging"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111405_bb0270","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2174\/156652413804486269","article-title":"The influence of macrophages and the tumor microenvironment on natural killer cells","volume":"13","author":"Krneta","year":"2013","journal-title":"Curr. Mol. Med."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111405_bb0275","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.it.2003.10.012","article-title":"NK cell and DC interactions","volume":"25","author":"Cooper","year":"2004","journal-title":"Trends Immunol."},{"issue":"2","key":"10.1016\/j.cellsig.2024.111405_bb0280","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.canlet.2011.12.020","article-title":"Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO","volume":"318","author":"Li","year":"2012","journal-title":"Cancer Lett."},{"issue":"6","key":"10.1016\/j.cellsig.2024.111405_bb0285","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1084\/jem.20062512","article-title":"Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression","volume":"204","author":"Deaglio","year":"2007","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.cellsig.2024.111405_bb0290","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/cmi.2013.10","article-title":"NK cell-based immunotherapy for malignant diseases","volume":"10","author":"Cheng","year":"2013","journal-title":"Cell. Mol. Immunol."},{"issue":"8","key":"10.1016\/j.cellsig.2024.111405_bb0295","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","volume":"141","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111405_bb0300","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/j.seminhematol.2023.02.002","article-title":"The natural killer cell immunotherapy platform: an overview of the landscape of clinical trials in liquid and solid tumors","volume":"60","author":"Piccinelli","year":"2023","journal-title":"Semin. Hematol."},{"issue":"5","key":"10.1016\/j.cellsig.2024.111405_bb0305","first-page":"501","article-title":"Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2","volume":"3","author":"Rosenberg","year":"1984","journal-title":"J. Biol. Response Mod."},{"issue":"5","key":"10.1016\/j.cellsig.2024.111405_bb0310","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/1097-0142(19950901)76:5<840::AID-CNCR2820760519>3.0.CO;2-R","article-title":"Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma","volume":"76","author":"Hayes","year":"1995","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111405_bb0315","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0959-8049(05)80028-0","article-title":"Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases","volume":"30a","author":"Keilholz","year":"1994","journal-title":"Eur. J. Cancer (Oxford, England\u202f: 1990)"},{"issue":"2","key":"10.1016\/j.cellsig.2024.111405_bb0320","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2003-12-4187","article-title":"Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance","volume":"105","author":"Kobayashi","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cellsig.2024.111405_bb0325","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10110423","article-title":"TGF\u03b2 imprinting during activation promotes natural killer cell cytokine hypersecretion","volume":"10","author":"Foltz","year":"2018","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.cellsig.2024.111405_bb0330","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2006-05-024315","article-title":"Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors","volume":"109","author":"Lundqvist","year":"2007","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cellsig.2024.111405_bb0335","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16030533","article-title":"Impact of KIR-HLA genotype on natural-killer-cell-based immunotherapy for preventing hepatocellular carcinoma after living-donor liver transplantation","volume":"16","author":"Tanimine","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.cellsig.2024.111405_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.879452","article-title":"A phase I study of Locoregional high-dose autologous natural killer cell therapy with hepatic arterial infusion chemotherapy in patients with locally advanced hepatocellular carcinoma","volume":"13","author":"Bae","year":"2022","journal-title":"Front. Immunol."},{"issue":"11","key":"10.1016\/j.cellsig.2024.111405_bb0345","doi-asserted-by":"crossref","DOI":"10.1002\/onco.13899","article-title":"Adoptive transfer of autologous invariant natural killer T cells as immunotherapy for advanced hepatocellular carcinoma: a phase I clinical trial","volume":"26","author":"Gao","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.cellsig.2024.111405_bb0350","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.2147\/JHC.S416933","article-title":"Efficacy of invariant natural killer T cell infusion plus Transarterial embolization vs Transarterial embolization alone for hepatocellular carcinoma patients: a phase 2 randomized clinical trial","volume":"10","author":"Guo","year":"2023","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"3","key":"10.1016\/j.cellsig.2024.111405_bb0355","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00262-021-03005-3","article-title":"Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma","volume":"71","author":"Ohira","year":"2022","journal-title":"Cancer Immunol. Immunother. CII"},{"issue":"6","key":"10.1016\/j.cellsig.2024.111405_bb0360","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15061743","article-title":"Addressing natural killer cell dysfunction and plasticity in cell-based cancer therapeutics","volume":"15","author":"Coyle","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111405_bb0365","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12943-022-01672-z","article-title":"NK cells and solid tumors: therapeutic potential and persisting obstacles","volume":"21","author":"Tong","year":"2022","journal-title":"Mol. Cancer"},{"issue":"14","key":"10.1016\/j.cellsig.2024.111405_bb0370","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1158\/1078-0432.CCR-18-3183","article-title":"Engineering the TGF\u03b2 receptor to enhance the therapeutic potential of natural killer cells as an immunotherapy for neuroblastoma","volume":"25","author":"Burga","year":"2019","journal-title":"Clin. Cancer Rese."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111405_bb0375","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000246","article-title":"Overcoming hypoxia-induced functional suppression of NK cells","volume":"8","author":"Solocinski","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111405_bb0380","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1038\/s41467-018-04719-2","article-title":"Amino acid-dependent cMyc expression is essential for NK cell metabolic and functional responses in mice","volume":"9","author":"Loftus","year":"2018","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.cellsig.2024.111405_bb0385","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/14653240801965156","article-title":"Functional characterization of interleukin-15 gene transduction into the human natural killer cell line NKL","volume":"10","author":"Jiang","year":"2008","journal-title":"Cytotherapy"},{"issue":"10","key":"10.1016\/j.cellsig.2024.111405_bb0390","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1182\/blood.V91.10.3850","article-title":"Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo","volume":"91","author":"Nagashima","year":"1998","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111405_bb0395","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/jhep.2001.20796","article-title":"Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12","volume":"33","author":"Barajas","year":"2001","journal-title":"Hepatology (Baltimore, Md)."},{"issue":"11","key":"10.1016\/j.cellsig.2024.111405_bb0400","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.4049\/jimmunol.173.11.6635","article-title":"IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice","volume":"173","author":"Harada","year":"2004","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111405_bb0405","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/hep.22296","article-title":"CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo","volume":"48","author":"Gonzalez-Carmona","year":"2008","journal-title":"Hepatology (Baltimore, Md)."},{"issue":"6","key":"10.1016\/j.cellsig.2024.111405_bb0410","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1158\/1535-7163.MCT-13-0722","article-title":"Immunotherapy for hepatoma using a dual-function vector with both immunostimulatory and pim-3-silencing effects","volume":"13","author":"Guo","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.cellsig.2024.111405_bb0415","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00262-010-0831-3","article-title":"Antitumor activity of type I and type III interferons in BNL hepatoma model","volume":"59","author":"Abushahba","year":"2010","journal-title":"Cancer Immunol. Immunother. CII"},{"issue":"4","key":"10.1016\/j.cellsig.2024.111405_bb0420","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/sj.cgt.7700453","article-title":"Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo","volume":"9","author":"Schirrmann","year":"2002","journal-title":"Cancer Gene Ther."},{"issue":"4","key":"10.1016\/j.cellsig.2024.111405_bb0425","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/blood.V100.4.1265.h81602001265_1265_1273","article-title":"Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction","volume":"100","author":"Uherek","year":"2002","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.cellsig.2024.111405_bb0430","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030660","article-title":"Characterization of a novel third-generation anti-CD24-CAR against ovarian Cancer","volume":"20","author":"Klapdor","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"10\u221211","key":"10.1016\/j.cellsig.2024.111405_bb0435","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41417-020-00259-4","article-title":"Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma","volume":"28","author":"Guo","year":"2021","journal-title":"Cancer Gene Ther."},{"issue":"8","key":"10.1016\/j.cellsig.2024.111405_bb0440","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.7150\/jca.39972","article-title":"Glypican-3: a new target for diagnosis and treatment of hepatocellular carcinoma","volume":"11","author":"Guo","year":"2020","journal-title":"J. Cancer"},{"issue":"2","key":"10.1016\/j.cellsig.2024.111405_bb0445","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ymthe.2017.12.012","article-title":"Development of GPC3-specific chimeric antigen receptor-engineered natural killer cells for the treatment of hepatocellular carcinoma","volume":"26","author":"Yu","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cellsig.2024.111405_bb0450","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.2147\/CMAR.S253565","article-title":"DNAM1 and 2B4 costimulatory domains enhance the cytotoxicity of anti-GPC3 chimeric antigen receptor-modified natural killer cells against hepatocellular Cancer cells in vitro","volume":"12","author":"Huang","year":"2020","journal-title":"Cancer Manag. Res."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111405_bb0455","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1038\/s41467-020-18444-2","article-title":"Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma","volume":"11","author":"Tseng","year":"2020","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.cellsig.2024.111405_bb0460","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.29496","article-title":"Recent developments of c-met as a therapeutic target in hepatocellular carcinoma","volume":"67","author":"Bouattour","year":"2018","journal-title":"Hepatology (Baltimore, Md)."},{"issue":"44","key":"10.1016\/j.cellsig.2024.111405_bb0465","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.1038\/onc.2017.209","article-title":"Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers","volume":"36","author":"Liu","year":"2017","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.cellsig.2024.111405_bb0470","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-15-1408","article-title":"PD-1hi identifies a novel regulatory B-cell population in human hepatoma that promotes disease progression","volume":"6","author":"Xiao","year":"2016","journal-title":"Cancer Discov."},{"issue":"7655","key":"10.1016\/j.cellsig.2024.111405_bb0475","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.cellsig.2024.111405_bb0480","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/hep.30593","article-title":"Blocking triggering receptor expressed on myeloid Cells-1-positive tumor-associated macrophages induced by hypoxia reverses immunosuppression and anti-programmed cell death ligand 1 resistance in liver cancer","volume":"70","author":"Wu","year":"2019","journal-title":"Hepatology (Baltimore, Md)."},{"key":"10.1016\/j.cellsig.2024.111405_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111628","article-title":"Enhanced NK cell activation via eEF2K-mediated potentiation of the cGAS-STING pathway in hepatocellular carcinoma","volume":"129","author":"Xu","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.cellsig.2024.111405_bb0490","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.601661","article-title":"The role of TIM-3 in hepatocellular carcinoma: a promising target for immunotherapy?","volume":"10","author":"Ganjalikhani Hakemi","year":"2020","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.cellsig.2024.111405_bb0495","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1273309","article-title":"PD-L1, Galectin-9 and CD8(+) tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma","volume":"6","author":"Sideras","year":"2017","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.cellsig.2024.111405_bb0500","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000058","article-title":"Immunologic features of patients with advanced hepatocellular carcinoma before and during Sorafenib or anti-programmed Death-1\/programmed death-L1 treatment","volume":"10","author":"Macek Jilkova","year":"2019","journal-title":"Clin. Transl. Gastroenterol."},{"issue":"4","key":"10.1016\/j.cellsig.2024.111405_bb0505","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellsig.2024.111405_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111681","article-title":"Anti-PD-1 therapy reverses TIGIT(+)CD226(+)NK depletion in immunotherapy resistance of hepatocellular carcinoma through PVR\/TIGIT pathway","volume":"130","author":"Wang","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.cellsig.2024.111405_bb0515","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.4049\/jimmunol.146.5.1571","article-title":"Analysis of Fc gamma RIII (CD16) membrane expression and association with CD3 zeta and Fc epsilon RI-gamma by site-directed mutation","volume":"146","author":"Lanier","year":"1991","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111405_bb0520","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2005-04-1351","article-title":"Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion","volume":"107","author":"Bryceson","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cellsig.2024.111405_bb0525","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001930","article-title":"Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas","volume":"9","author":"Arnone","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cellsig.2024.111405_bb0530","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3389\/fimmu.2018.00441","article-title":"NKG2D: a master regulator of immune cell responsiveness","volume":"9","author":"Wensveen","year":"2018","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.cellsig.2024.111405_bb0535","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1083\/jcb.201712085","article-title":"Shedding of CD16 disassembles the NK cell immune synapse and boosts serial engagement of target cells","volume":"217","author":"Srpan","year":"2018","journal-title":"J. Cell Biol."},{"issue":"7","key":"10.1016\/j.cellsig.2024.111405_bb0540","doi-asserted-by":"crossref","DOI":"10.3390\/cells12070996","article-title":"Derivation and preclinical characterization of CYT-303, a novel NKp46-NK cell engager targeting GPC3","volume":"12","author":"Arulanandam","year":"2023","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.cellsig.2024.111405_bb0545","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2024.01.028","article-title":"Increased Siglec-9\/Siglec-9L interactions on NK cells predict poor HCC prognosis and present a targetable checkpoint for immunotherapy","volume":"80","author":"Xiao","year":"2024","journal-title":"J. Hepatol."},{"issue":"33","key":"10.1016\/j.cellsig.2024.111405_bb0550","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1200\/JCO.2013.51.3002","article-title":"Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study","volume":"31","author":"Thomas","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cellsig.2024.111405_bb0555","first-page":"145","article-title":"Preclinical evaluation of adoptive cell therapy for patients with metastatic renal cell carcinoma","volume":"29","author":"Markel","year":"2009","journal-title":"Anticancer Res."},{"issue":"14","key":"10.1016\/j.cellsig.2024.111405_bb0560","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells","volume":"33","author":"Stevanovi\u0107","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.cellsig.2024.111405_bb0565","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cellsig.2024.111405_bb0570","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2009.07.013","article-title":"Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients","volume":"52","author":"Chew","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cellsig.2024.111405_bb0575","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.omto.2019.03.004","article-title":"Fludarabine as an adjuvant improves Newcastle disease virus-mediated antitumor immunity in hepatocellular carcinoma","volume":"13","author":"Meng","year":"2019","journal-title":"Mol. Ther. Oncol."},{"issue":"9","key":"10.1016\/j.cellsig.2024.111405_bb0580","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.4049\/jimmunol.1302091","article-title":"CTLA-4 is expressed by activated mouse NK cells and inhibits NK cell IFN-\u03b3 production in response to mature dendritic cells","volume":"192","author":"Stojanovic","year":"2014","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.cellsig.2024.111405_bb0585","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.ymthe.2018.07.013","article-title":"Superagonist IL-15-armed oncolytic virus elicits potent antitumor immunity and therapy that are enhanced with PD-1 blockade","volume":"26","author":"Kowalsky","year":"2018","journal-title":"Mol. Ther."},{"issue":"6","key":"10.1016\/j.cellsig.2024.111405_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic Virotherapy promotes Intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell"}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656824003735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656824003735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T21:08:14Z","timestamp":1734642494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656824003735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":118,"alternative-id":["S0898656824003735"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2024.111405","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NK cell-based immunotherapy in hepatocellular carcinoma: An attractive therapeutic option for the next decade","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2024.111405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111405"}}